TY  - JOUR

T1  - Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis.

JO  - Journal of Clinical Oncology

PY  - 2013/05/20

AU  - Latimer N

AU  - Abrams KR

AU  - Amonkar M

AU  - Stapelkamp C

AU  - Swann RS

ED  - 

DO  - DOI: 10.1200/jco.2013.31.15_suppl.9044

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 15_suppl

SP  - 9044

EP  - 9044

Y2  - 2024/12/22

ER  -